The ACR’s 2018 Legislative & Regulatory Priorities

Members can also contribute to RheumPAC, the ACR’s nonpartisan lobbying arm.

The ACR’s efforts are “not designed to be partisan,” Dr. Worthing says. “This is almost always a bipartisan effort, and the ACR works with leaders on both sides of the aisle to ensure we best represent our members, our patients and our profession.”

Kelly April Tyrrell writes about health, science and health policy. She lives in Madison, Wis.

Reference

Alberta, T, Bade R. Paul Ryan sees his wild Washington journey coming to an end. Politico Magazine. 2017 Dec 18.

A recent Politico article outlined the looming agenda facing Congress as 2018 begins: Fund the government, raise the debt ceiling, modify spending caps, address healthcare subsidies, allocate additional funds for disaster relief, and address the status of millions of undocumented young immigrants.1 Amid all that activity, the ACR, through its Government Affairs Committee (GAC) and…

The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

Reference

The ACR’s 2018 Legislative & Regulatory Priorities

Marching to the Biosimilar Beat: Questions on Rollout Remain

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

High Cost of Specialty Drugs Demands Action

Reference

Related Articles